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Abstract
Background: Next generation sequencing (NGS) technology has been rapidly introduced into basic and translational
research in oncology, but the reduced availability of fresh frozen (FF) tumor tissues and the poor quality of
DNA extracted from formalin-fixed, paraffin-embedded (FFPE) has significantly impaired this process in the
field of solid tumors. To evaluate if data generated from FFPE material can be reliably produced and potentially used in
routine clinical settings, we performed whole exome sequencing (WES) from tumor samples of Gastrointestinal stromal
tumors (GIST), either extracted FF or FFPE, and from matched normal DNA.
Methods: We performed whole exome enrichment and sequencing at 100bp in paired end on four GIST samples,
either from FFPE or fresh-frozen tissue, and from matched normal DNA.
Results: The integrity of DNA extracted from FFPE was evaluated by a modified RAPD PCR method, thus identifying
high quality (HQ) and low quality (LQ) FFPE. DNA library production and exome capture was feasible for both classes of
FFPE, despite the smaller yield and insert size of LQ-FFPE. WES produced data of equal quality from FF and FFPE,
while only HQ-FFPE yielded an amount of data comparable to FF samples. Bioinformatic analysis showed that
the percentage of variants called both in FF and FFPE samples was very high in HQ-FFPE, reaching 94-96 %
of the total number of called variants. Classification of somatic variants by nucleotide substitution type
showed that HQ-FFPE and FF had similar mutational profiles, while LQ-FFPE samples carried a much higher
number of mutations than the FF counterpart, with a significant enrichment of C > T/G > A substitutions.
Focusing on potential disease-related variants allowed the discovery of additional somatic variants in GIST
samples, apart from the known oncogenic driver mutation, both from sequencing of FF and FFPE material.
False positive and false negative calls were present almost exclusively in the analysis of FFPE of low quality.
On the whole this study showed that WES is feasible also on FFPE specimens and that it is possible to easily
select FFPE samples of high quality that yield sequencing results comparable to the FF counterpart.
Conclusions: WES on FFPE material may represent an important and innovative source for GIST research and
for other solid tumors, amenable of possible application in clinical practice.
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Background
Massively parallel sequencing by next generation se-
quencing (NGS) technology has been rapidly introduced
into basic and translational research in oncology, due to
the ability of identifying the complete landscape of gen-
etic alterations in many tumor types [1–5].
Most genotyping studies have been performed using
fresh frozen (FF) tissues, and have provided great in-
sights into the cancer molecular biology. However, the
higher quality of DNA extracted from FF tissue is offset
by the reduced availability of the samples, which does
not allow to perform large-scale retrospective studies.
Therefore in the recent years, many efforts have been
addressed to set up strategies to apply massively parallel
sequencing technology to formalin-fixed, paraffin-
embedded (FFPE) specimens. While FFPE specimens are
now frequently analyzed by amplicon-based or targeted-
capture NGS panels [6–10], the possibility to reliably
perform whole genome or whole exome sequencing
(WES) in archival tumor samples still represents a chal-
lenge, both from the technical and bioinformatic point
of view [11–16].
Gastrointestinal stromal tumors (GIST) are mesenchy-
mal tumors that most frequently arise in the gastrointes-
tinal tract. GIST are characterized by mutually exclusive
KIT (85 %) or platelet-derived growth factor receptor
alpha (PDGFRA) (5-10 %) gain of function mutations,
leading to constitutive ligand-independent activation of
receptor signalling [17–19]. The knowledge about the
oncogenic mechanisms responsible for GIST onset
paved the way for the effective introduction of
tyrosine-kinase inhibitors (TKIs) in the standard treat-
ment protocols and the recognition of the clinical im-
pact and predictive significance of molecularly-defined
subtypes [20, 21]. Up to now, about 10-15 % of GIST
do not exhibit neither KIT or PDGFRA mutations
and have been defined as KIT/PDGFRA wild type
(WT), which represent an extremely heterogeneous
subgroup, characterized by different subsets with dis-
tinct molecular hallmarks [22, 23].
In this complex scenario, in which the molecular biol-
ogy plays a certain relevant role, but the FF specimens
are often not available, the feasibility of high-throughput
genomic studies on FFPE tissue would allow to perform
larger prospective and retrospective studies on all these
small subsets of GIST, expanding the reproducibility and
the reliability of the data.
This study is aimed to develop a reliable approach to
perform WES on archival tumor samples from GIST pa-
tients, in order to evaluate how data generated from
FFPE material can be generated and potentially used in
routine clinical settings. Herein we reported the first piv-
otal study on the comparison between data obtained by
whole exome analysis on four FFPE and FF GIST
samples, showing an high degree of concordance for all
the variants found, including common polymorphism
and novel somatic variants.
Results and discussion
FFPE-DNA integrity analysis
To be able to produce clinically relevant and reliable
data from FFPE samples it is necessary to quantify the
degree of DNA degradation of FFPE-derived DNA. We
used two different PCR-based methods, that produce a
qualitative and quantitative assessment of DNA integrity.
The first is a modification of the Random Amplified
Polymorphic DNA assay (RAPD), that uses degenerated
primers to amplify multiple fragments, of different
length on the genome. DNA derived from FF samples
amplifies a prevalent pool of fragments of around
500 bp, with multiple bands of higher size, while FFPE-
derived DNA is either of high quality (HQ-FFPE) and
shows the 500 bp band as the longest amplifiable frag-
ment (GIST193, GIST174, GIST165), or of low quality
(LQ-FFPE), thus showing only shorter amplified frag-
ments of no more than 300–400 bp (GIST127) (Fig. 1a).
These two categories of FFPE-derived DNA are identifi-
able in a larger panel of samples, where we detected
HQ-FFPE DNA in approximately 40-50 % of samples
(data not shown).
The other method is a quantitative-PCR that amplifies
fragments of 41 bp, 129 bp and 305 bp of a highly con-
served single copy gene. DNA quality is assessed by nor-
malizing the concentration obtained with the 129 and
305 bp amplicon against the 41 bp amplicon (Q-ratio),
where a Q-ratio of 1 represents intact DNA. This assay
shows results in agreement with RAPD assay, where
HQ-FFPE have a Q129/Q41 ratio above 0.5, and LQ-
FFPE below 0.25 (Fig. 1b). Similarly, Q301/Q41 ratio of
HQ-FFPE is a measurable value (>0.1), while in LQ-
FFPE the amplification of the 301 bp fragment is almost
undetectable (Q-ratio ≈ 0) (Fig. 1c).
Exome enrichment and sequencing of FFPE samples
DNA library preparation and exome enrichment with
Nextera Rapid Capture Exome Enrichment kit (Illumina)
was then performed for three HQ-FFPE and one LQ-
FFPE, for the paired FF tumor samples and normal
counterpart from peripheral blood DNA. Tagmentation
was performed on 100 ng of DNA, thus reaching an op-
timal library yield and size distribution for all the sam-
ples, except for the LQ-FFPE DNA (Additional file 1:
Table S2). All the samples, including those derived from
HQ-FFPE, yielded between 1.8 and 2.7 ug of DNA li-
braries, while the one derived from LQ-DNA reached
the necessary 0.5 ug only with two independent reac-
tions that were pooled. Average library size for FF- and
PB-derived DNA was 295 ± 5 bp, while HQ-FFPE DNA
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yielded libraries of 230–240 bp, and LQ-FFPE did not
exceed 190 bp (Additional file 1: Figure S1).
Libraries were then indexed, pooled and enriched for
the exonic component, and then sequenced at 100 bp in
paired – end. Lane-specific sequencing quality parame-
ters (Density, % of clusters passing filter, % of bases ≥
Q30) were similar for FF and FFPE tumor samples, and
for PB-derived DNA (Additional file 1: Table S3). In par-
ticular, the Average Q-score and the % of bases with Q-
score ≥Q30 were comparable for all the samples ana-
lyzed (Additional file 1: Table S4).
Despite similar performance of clustering and sequen-
cing the LQ-FFPE sample (GIST127_FFPE) showed a
much lower data yield (14 million reads), while HQ-
FFPE produced the same amount of reads as FF samples
(55 million reads for FF vs 56 million reads for HQ-
FFPE samples) (Table 1). The percentage of PCR dupli-
cates was approximately the same for all the samples,
while the percentage of bases trimmed due to sequen-
cing falling into adapters, primers and indexes was low
for FF, PB and HQ-FFPE, while it was relevant in the
GIST127_FFPE sample (20.7 vs 9.2 % on average). This
result was expected, since DNA library dimension of the
LQ-FFPE sample was below 200 bp. This is reflected
also by the value of the average insert size, that is pro-
portional to DNA integrity, with values proportionally
decreasing from PB to FF, to HQ-FFPE and lastly to LQ-
FFPE samples (Additional file 1: Figure S2).
Almost all the sequences after adaptor trimming and
PCR duplicate removal mapped on the human genome
hg19, since the percentage of mapped reads exceeded
98 % (Table 1).
Average coverage of the target exome region was com-
parable for FF- and FFPE-derived samples (FF: 55X -
71X; FFPE: 58X – 77X), except for the LQ-FFPE, that
reached an average coverage of 17X (Table 2). Similarly,
the percentage of the target region covered at least 10X
was very high for both FF and FFPE-derived samples
(92-96 %), while it was below 60 % for GIST127_FFPE
(Table 2).
Fig. 1 Quality control of DNA extracted from FFPE samples. a RAPD PCR performed on FF tumors and FFPE –derived DNA. b-c. KAPA HgDNA
quantitative PCR QC kit, summarized as Q-score of the 129 bp vs the control 41 bp amplicon (b) and as the 305 bp vs the 41 bp (c)
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Off-target sequencing is related to the amount of reads
mapping outside the region targeted by the exonic cap-
ture, that is of 37 Mb with the Nextera Rapid Capture
assay. The amount of off-target sequencing was from 39
to 53 %, the smaller value related to the LQ-FFPE sam-
ple (Additional file 1: Figure S3).
Comparison of WES results of FFPE and FF samples
Sequencing data was analyzed with the pipeline de-
scribed in the Methods section. First of all the degree of
concordance between FFPE and Fresh samples was com-
puted considering all the variants called, including com-
mon polymorphism and novel variants mapping on the
37 Mb Exome target region.
As shown in Fig. 2 the percentage of shared variants,
called both in FF and FFPE samples, is very high in HQ-
FFPE, reaching 94-96 % of the total number of called
variants. Conversely, in GIST127 sample the FFPE sam-
ples loses almost half of the variants called in the FF
sample, since the number of variants not determined in
FFPE is up to 45 % of the total number.
We selected only the somatic single nucleotide vari-
ants (SNVs) and then classified them based on the type
of nucleotide substitution (Fig. 3). In all the HQ-FFPE
the number of mutations falling in the different classes
are comparable to the corresponding FF sample while in
the GIST127 FFPE the total number of putative somatic
SNVs is higher than the corresponding FF sample and in
particular the most enriched class of mutation is the
C > T/G > A as expected by cytosine deamination due to
formalin fixation.
To identify the disease-related variants, we further re-
stricted the dataset to the somatic non-synonimous
(missense, nonsense and stop loss) SNVs and InDels lo-
cated in the coding region and splicing sites.
By this we highlighted 4, 13, 27 and 26 somatic muta-
tions in the four FF samples (GIST193, GIST165,
GIST174 and GIST127, respectively, Additional file 1:
Table 2 Average coverage and percentage of target enriched region covered at least 1X and 10X
Patient Sample Average Coverage 37 Mb % Nextera covered > = 1X % Nextera covered > = 10X
GIST193 FF 71X 99.2 % 96.5 %
FFPE 65X 99.2 % 95.8 %
PB 43X 99.2 % 93.7 %
GIST165 FF 59X 99.2 % 95.0 %
FFPE 58X 99.2 % 94.9 %
PB 47X 99.2 % 93.6 %
GIST174 FF 61X 99.0 % 92.2 %
FFPE 77X 99.0 % 94.3 %
PB 52X 99.3 % 95.0 %
GIST127 FF 55X 99.0 % 92.9 %
FFPE 17X 93.0 % 58.1 %
PB 46X 99.0 % 92.2 %
Table 1 Sequencing quality and statistical parameters in FF, FFPE and PB samples
Patient Sample Total n° Reads High Quality
Bases (n°)
% Trimmed Bases Unique Reads (n°) % PCR duplicate n° Mapped Reads % Mapped Reads
GIST193 FF 63,523,138 5.84E + 09 8.1 % 58,598,506 7.8 % 57,879,604 98.8 %
FFPE 54,852,570 4.97E + 09 9.4 % 49,208,829 10.3 % 48,499,561 98.6 %
PB 42,361,296 3.80E + 09 10.3 % 39,964,111 5.7 % 39,385,105 98.6 %
GIST165 FF 53,644,770 4.95E + 09 7.7 % 49,587,098 7.6 % 49,019,552 98.9 %
FFPE 50,570,884 4.59E + 09 9.3 % 45,332,397 10.4 % 44,682,820 98.6 %
PB 42,235,292 3.87E + 09 8.3 % 39,957,754 5.4 % 39,460,107 98.8 %
GIST174 FF 56,267,604 5.10E + 09 9.3 % 52,033,110 7.5 % 51,338,819 98.7 %
FFPE 64,625,134 5.87E + 09 9.2 % 58,169,850 10.0 % 57,529,198 98.9 %
PB 52,136,904 4.69E + 09 10.0 % 48,822,001 6.4 % 48,110,730 98.5 %
GIST127 FF 48,223,180 4.42E + 09 8.4 % 44,804,080 7.1 % 44,294,468 98.9 %
FFPE 14,203,932 1.14E + 09 20.7 % 12,496,962 12.0 % 12,310,812 98.1 %
PB 43,078,472 3.86E + 09 10.4 % 40,476,585 6.0 % 39,924,959 98.4 %
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Table S5). These mutations were defined as Shared Vari-
ants if present also in FFPE (3, 13, 24 and 13, respect-
ively). We confirmed the presence of known KIT and
PDGFRA mutations also in FFPE samples (Table 3,
Fig. 4a, b), and also the presence of truncating SDHA
mutation in GIST193, even if not reported in the list of
somatic variants, being a germinal mutation with LOH
in the tumor sample (Fig. 4c). Overall WES, both per-
formed on FF and FFPE samples, allowed the discovery
of other somatic variants in GIST samples, apart from
the known oncogenic driver mutations. It is worth not-
ing that the number of mutations carried by SDHA-
driven tumors is almost negligible with respect all other
GIST molecular subgroups; moreover, WES analysis
proved to be informative even for tumors driven by
well-known molecular alterations, being able to identify
clinically relevant mutations, as in the case of PTEN
R233X mutation in GIST174, evidenced both in FF and
FFPE sample (Additional file 1: Table S5).
False Negative variants, meaning those not called in
the FFPE sample, were very few in HQ-FFPE (0–3 per
sample), while very frequent in LQ-FFPE sample (13/26
variants identified in the FF sample). Anyway False
Negative calls were mostly due to low coverage in FFPE
samples (Fig. 4d). Conversely False Positive variants, i.e.,
present only in the FFPE samples, were negligible in
HQ-FFPE (only one FP in each sample), but are particu-
larly enriched in LQ-FFPE where they represented more
than 60 % of the variants identified in FFPE (20 out of
33, Additional file 1: Table S5). Most of the false positive
calls in the low quality FFPE were C > T and G > A sub-
stitutions (75 %). These events were real artifacts intro-
duced by formalin fixation and not sequencing errors,
since they were confirmed by Sanger sequencing
(Fig. 4e).
It is well known that GIST represent an heterogeneous
set of different clinical and biological entities, each of
which characterized by a unique molecular profile,
Fig. 2 Concordance between FF and FFPE data. All the variants called, including common polymorphism and novel variants mapping on the
37 Mb Exome target region were classified as Shared if called in both FF and FFPE samples, as False Negative (FN) if called only in FF sample, as
False Positive (FP) if detected only in FFPE, or ND if not sufficiently covered in either type of sample
Astolfi et al. BMC Genomics  (2015) 16:892 Page 5 of 11
highlighting the relevant role of molecular biology in
this disease, both in research settings and in clinical
practice. In this contest, massively parallel sequencing
emerged as a promising tool, allowing a complete pic-
ture of genetic alterations in many tumor types, includ-
ing GIST [23, 24]. However, up to now this technology
has been severely limited by the lack of FF tissue banks,
needful for conducting large-scale studies, which are re-
quired in a rare tumor as GIST, in order to obtain reli-
able and transferable data into clinical practice.
Some evidences have been already reported on the
feasibility of genome sequencing on FFPE specimens,
representing the widest archive of tumor samples
[11–16]. Herein we reported the first pivotal study on
the comparison between data obtained by whole ex-
ome analysis on four FFPE and FF GIST samples,
showing an high degree of concordance for all the
variants found, including common polymorphism and
novel somatic variants.
Indeed we know that targeted sequencing of clinically
relevant mutation panels has become a feasible ap-
proach, that is increasingly applied in clinical practice to
aid diagnosis and treatment choice [10, 25]. However
there are many advantages to WES over targeted NGS
approaches: first of all, given that the list of clinically ac-
tionable or informative mutations is increasing, the tar-
geted panels become progressively less beneficial for
clinical application; at the same time clinical WES is
slowly turning into a rapid, cost-efficient, and straight-
forward technique, that can be amenable to routine ap-
plication in clinical settings. Thus, given that the
number of informative cancer mutations is rising, the
application of WES analysis on archived tumor samples
will definitely become an urgent need. Therefore, our re-
sults demonstrate that this analysis is not only feasible
on at least a significant proportion of FFPE tumor sam-
ples, but also that the results are reliable, and almost
superimposable to FF samples.
There are very few other reports on this topic; in par-
ticular, Hedegaard et al. achieved only partially positive
results, with a poor percentage of successful exome
library preparation and sequencing from FFPE (29 %)
and an overly high representation of PCR duplicates
(30 %), highlighting some reproducible issues of WES se-
quencing from FFPE, as the shorter insert sizes and the
presence of longer adapter sequences in the reads [15].
Fig. 3 Total number of somatic SNVs detected in FF and FFPE samples, stratified based on the type of nucleotide substitution
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Our approach has solved these technical issues, since we
were able to produce DNA libraries from all the FFPE
samples, and keep the PCR duplicates at levels compar-
able to FF samples.
Conversely, Kerick et al. and Van Allen et al., both
using a different approach than ours for exome library
prep (Agilent SureSelect), have reported an high
reproducibility of SNV detection between FF and FFPE,
only slightly lower than ours, but both authors did not
take into account of clinically relevant somatic muta-
tions and did not correlate the sequencing performance
with FFPE quality [11, 16]. Here we show that not only
it is possible to achieve results comparable to FF when
performing exome sequencing on FFPE tumor samples,
Table 3 Detection of known pathogenic mutations carried by the GIST samples analyzed as evidenced by exome sequencing in FF
and FFPE samples
Patient Chr:Position GENE cDNA PROTEIN FF
Ref_Cov/Alt_Cov
(Ratio)
FFPE
Ref_Cov/Alt_Cov
(Ratio)
PB
Ref_Cov/Alt_Cov
(Ratio)
GIST174 4:55593661 KIT c.T1727C p.L576P 2/160 (98.8 %) 12/236 (95.2 %) 116/0 (0 %)
GIST165 4:55152093 PDGFRA c.A2525T p.D842V 109/35 (24.3 %) 57/32 (36.0 %) 110/0 (0 %)
GIST193 5:235345 SDHA c.C1151G p.S384X 4/50 (92.6 %) 5/38 (88.4 %) 23/24 (51.1 %)
Ref reference, Alt alternative, Cov Coverage
Fig. 4 Validation of selected somatic mutations by Sanger sequencing on FF and FFPE tumor DNA and on PB-derived DNA. a PDGFRA p.D842V
mutation detected in GIST165 tumor DNA from FF and FFPE samples. b KIT p.L576P mutation present in GIST174 patient, both in FF and FFPE. c
SDHA p.S384X detected in patient GIST193 in heterozygosis in the germline, and in homozygosis in tumor DNA (both from FF and FFPE). d False
negative LATS2 p.Q937X somatic stop-gain mutation. This mutation is present in both FF and FFPE samples, but fails to be detected by WES of
FFPE due to low coverage. e False positive GPR45 p.V203M missense variant. This putative mutation is a present only in FFPE and not in FF sample
from GIST127, probably due to cytosine deamination induced by formalin fixation
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but also that there are ways to score the quality of FFPE
DNA that predict the reliability of sequencing results,
with a degree of concordance with FF sample that is
over 94 %. Actually, as the predominant errors intro-
duced by WES on FFPE are the false positives due to
cytosine deamination (C > T and G > A substitutions),
that can represent up to 60 % of the called variants in
FFPE samples, we also show that by selecting only high
quality FFPE this bias becomes negligible. In fact we also
showed that low quality FFPE carries a higher muta-
tional burden, that is explained in part by cytosine de-
amination and also by the overall extent of DNA
damage, thus explaining why all categories of base sub-
stitutions are enriched in LQ-FFPE, anyway with a
marked predominance of transitions (10X – 15X) versus
transversions (2X – 6X).
The study results have important implications in
GIST’s translational research. The high degree of con-
cordance of the data would allow to expand the NGS
analysis to all archived GIST specimens, thus enlarging
the sample size analyzed. In a rare disease as GIST,
where it is methodologically difficult designing prospect-
ive studies due to their very low incidence, the possibil-
ity to open up the analysis to the all archived specimens,
may offer the opportunity to perform larger retrospect-
ive studies, using innovative technologies, without the
limit of availability of FF tumor tissue. Moreover, it may
also allow applying these more recent tools on the wide
case series of the historical conducted clinical trials, that
represent the main available source of well-selected
GIST patients, providing novel and more reliable inter-
pretations of these historic data [26, 27]. Finally, the pos-
sibility to perform genomic studies on a large number of
samples would also improve the knowledge on the bio-
logical background of many kinds of tumor, including
GIST, allowing to better define the real prognostic and
predictive value of several biological markers, not yet
transferred into clinical practice because of their role
still uncertain. This aspect is even more relevant for rare
cancers, as GIST, for which it is extremely difficult to
make studies with prognostic and predictive purpose, for
the need of an adequate number of patients to analyze
and follow for a long time.
Conclusions
Given the preliminary but promising results above-
reported, it is mandatory to confirm and validate all
technical steps, and all analytical processes, raising the
challenge of optimize and transfer this assay into clinical
practice [27]. Firstly, robust DNA extraction and sequen-
cing library construction protocols are required. Sec-
ondly, analytical protocols that can be applicable on
limited amounts of tissue and extracted DNA are
mandatory especially when the samples available for
testing come from small-core needle biopsies and fine-
needle aspirations. Finally, the analytical process should
be standardized, and validated in order to let this tech-
nology feasible for a clinical use.
In conclusion, WES on FFPE specimens may represent
an important and innovative source for GIST research,
and further investigations are required in order to better
assess the assay.
Methods
Sample collection
This study was approved by the institutional review
board of Azienda Ospedaliero-Universitaria Policlinico
S. Orsola-Malpighi, Bologna, Italy (approval number
113/2008/U/Tess). All patients provided written in-
formed consent. Tumor specimens were collected dur-
ing surgery and reviewed by the pathologist who cut a
portion to be snap-frozen and conserved in liquid nitro-
gen (FF). The tumor specimen was then fixed in 10 %
NBF (Formalin Solution, Neutral Buffered) for no less
than 6 h and not more than 72 h, then dehydrated and
included in paraffin (FFPE). For DNA extraction, at least
2–3 slices of 10 um of thickness were cut from the
paraffin block and superimposed to a 3um H&E-
stained slide. Clinical and biological data of the pa-
tients included in the study are listed in Additional
file 1: Table S1.
DNA extraction
Manual macrodissection of the tumoral area, identified by
superimposition of a H&E stained glass, was performed
on the FFPE slide using a scalpel. Macrodissected FFPE
and fresh frozen tissues were digested over-night at 56 °C
in ATL buffer with the addition of proteinase K (Qiagen).
DNA extraction was then continued with QIAamp DNA
micro kit (Qiagen). DNA from peripheral blood was ex-
tracted with QIAamp DNA mini kit following manufac-
turer’s instructions. DNA concentration was determined
with both spectrophotometric (Nanodrop) and fluoromet-
ric (Picogreen dsDNA kit, Life Technologies) methods.
On average, the concentration measured with picogreen
was half the concentration estimated with Nanodrop.
FFPE quality check
RAPD-modified method
This assay was taken from the RAPD method described
by (3) and modified as follows: 2.5 – 5 ng of DNA from
FFPE or FF DNA were amplified with 0.5 μM RAPD
primers (FW: 5'-aatcgggctg-3; REV: 5‘-gaaacgggtg-3')
with 0.5 U of KAPA 2G FAST HotStart TAQ polymerase
(Kapa Biosystems), 2 mM MgCl2, 200 μM dNTPs. PCR
was perfomed for 40 cycles (95 °C, 15 s; 37 °C, 15 s; 72 °C,
1 min).
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KAPA HgDNA quantification and QC kit
This assay is based on quantitative-PCR amplification of
a 41 bp, 129 bp and 305 bp fragment of a highly con-
served single copy gene (KAPA Human Genomic DNA
Quantification and QC Kit, Kapa Biosystems). 5 ng of
DNA were amplified with KAPA SybrFast qPCR Master
Mix on a ABI Prism 7900 HT (Applied Biosystems) fol-
lowing manufacturer’s instructions. The 41 bp amplicon
is used for absolute quantification of DNA samples
against a set of DNA standards. DNA quality is assessed
by normalizing the concentration obtained with the 129
and 305 bp amplicon against the one obtained with the
41 bp assay (Q-score). Theoretically integer DNA has an
optimal Q-score ≈ 1 for both the Q129/Q41 and the
Q305/Q41 ratios.
Next Generation sequencing
WES was performed on DNA isolated from fresh frozen
and FFPE tumor tissue and from matched normal per-
ipheral blood DNA. Whole exome libraries were pre-
pared in accordance with Nextera Rapid Capture Exome
Enrichment protocol (Illumina). Briefly 100 ng of gen-
omic DNA was tagmented (tagged and fragmented) by
the Nextera transposome technique to an average library
size of 290 bp (190–230 bp for the FFPE-derived tumor
samples). DNA Library dimension were measured with
DNA 1000 chip on the Agilent 2100 Bioanalyzer work-
station (Agilent). DNA libraries were then pooled, dena-
tured to single stranded DNA and hybridized to biotin-
labeled 80-mer probes designed to enrich 214,126 tar-
geted exonic regions, then eluted from magnetic beads.
Exome enriched DNA libraries were quality-checked
and sized with Agilent DNA 1000 or 7500 chips on the
Bioanalyzer 2100 (Agilent Technologies,Taiwan), then
quantified using a fluorometric assay (QuantIT Pico-
green assay, Life Technologies). 12pM paired-end librar-
ies were amplified and ligated to the flowcell by bridge
PCR, and sequenced at 2x100bp read length, using Illu-
mina Sequencing by synthesis (SBS) technology. An
average of 55 million reads for FF and of 46 million
reads for FFPE samples were obtained for WES analysis.
Bioinformatic analysis
Adapter removal and quality trimming were performed
with the tool AdapterRemoval using the default parame-
ters except the threshold for trimming low quality bases
(Q < 10), meaning that consecutive stretches of bases
from both the 5' and 3' end of the reads with Phred
Quality of 10 or lower were trimmed, and the minimum
read length set to 30 nucleotides.
After trimming, the short reads were mapped on the
human reference genome hg19 with BWA software. The
alignments were processed with samtools to remove
PCR duplicate and with GATK in order to perform local
realignment around the indel position, base quality score
recalibration and insertion/deletion calling (InDels),
while variation calling was performed with MuTect thus
identifying all the point mutations in the sample (SNVs).
Variants were considered for the further analysis if map-
ping on the 37 Mb Nextera target region, while the
remaining were defined as “off-target” and excluded.
This set of variants (SNVs and the InDels called with
Mutect and GATK respectively) detected in both Fresh
and FFPE samples was reduced in order to keep into ac-
count only the variant that are defined as “high-quality”
at least in one of the two samples according the follow-
ing criteria met in Fresh sample, FFPE sample or both:
MuTect/GATK filter label = KEEP/PASS, Depth of
coverage > 10, Ratio of alternate allele > = 0.2. The cover-
age of alternate and reference alleles were re-counted
with the function mpileup of samtools and no upper
limits in the depth of coverage was set.
The resulting dataset was considered to estimate the
agreement between FFPE and Fresh data. We defined:
– If depth of coverage < = 10, Undetermined variants
(ND);
– If depth of coverage >10:
O Shared variants, if variant is called in both FFPE
and Fresh samples;
O FFPE False positive, if variant is called in FFPE
and absent in Fresh sample;
O FFPE False negative, if variant is called in Fresh
and absent on FFPE sample.
To identify the tumor–related events, variants
present in dbSNP and 1000Genomes with frequency
greater than 1 % were excluded. Thus all the variants
either not reported, or present in dbSNP but with a
frequency lower that 1 % or with no frequency re-
ported were retained in the analysis. All variants from
the matched normal-tumor pairs that were unique in
the tumor sample were called as Somatic (using Sam-
tools mpileup funtion). To call the somatic variants
we relaxed the depth of coverage threshold to > = 6X
to take into account the higher multiplexing of PB
samples, the lower average coverage of poor quality
FFPE, and the need to increase the sensitivity of the
assay at the lower limit of detection. The whole set
of somatic variants was manually checked within the
BAM file in order to exclude alignment errors that in
most cases occur in repetitive regions. The effect of
coding SNV was predicted at the protein level with a
suite of computational tools, such as SIFT and PRO-
VEAN. Truncations and frameshift mutations were
analyzed in relation to the annotations available on
the protein sequence (e.g., from UniProt, PFAM,
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SCOP) in order to identify possible domain/site loss,
disruption or gain that can affect protein function.
Sanger sequencing
Validation of selected somatic variants was performed
on DNA extracted from FF and FFPE tumor samples
and from PB as a source of germline DNA. The genomic
region surrounding the putative mutation was amplified
with Polymerase Chain Reaction (PCR) using specific
primer pairs designed with Primer Express 3.0 Software
(Applied Biosystem). PCR products were then purified
with the Qiaquick PCR purification kit (Qiagen, Milan,
Italy) and sequenced on both strands using the Big Dye
Terminator v1.1 Cycle Sequencing kit (Applied Biosys-
tems). Sanger sequencing was performed on ABI 3730
Genetic Analyzer (Applied Biosystems).
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Additional file 1: Table S1. Clinical and biological data of the patients
included in the study. Table S2. Tagmented DNA library and post-enrichment
pooled library yield and average size. Table S3. Lane-specific sequencing
quality parameters (cluster density, percentage of clusters passing filter, total
number or reads passing filter and percentage of bases with quality ≥ Q30).
Table S4. Sample-specific sequencing quality scores (percentage of bases with
quality ≥ Q30 and average Q-score). Table S5. List of somatic somatic
disease-related mutations (non-synonimous and nonsense SNVs and InDels
located in the coding region and splicing sites). Variants are flagged as shared
if present both in FF and FFPE samples, FP if called only in FFPE and FN if
called only in FF. Ref: reference; Alt: alternative; Cov: Coverage. Figure S1.
Tagmented DNA library size distribution as analyzed by Agilent DNA 1000 kit.
Figure S2. Average insert size of the exome libraries sequenced at 100bp x 2.
Figure S3. Percentage of reads mapping on-target and off-target, i.e., outside
the 37Mb Nextera target region used for exome enrichment. (DOCX 100 kb)
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